Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Cancer-associated stroke: identifying distinct phenotypes and predicting recurrence risk

Andrew Demchuk, MD, FRCPC, University of Calgary, Calgary, Canada, discusses the rising burden of cancer-associated stroke, highlighting the challenge of determining when cancer is directly causing a stroke versus when the two conditions coexist independently. Prof. Demchuk notes that a dominant phenotype of cancer-associated coagulopathy is emerging, particularly in patients with adenocarcinomas and advanced cancers, characterized by a distinct pattern of diffusion abnormalities and elevated D-dimer levels, which carries a high recurrence risk. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Cancer obviously is one of the most common conditions. And so it’s not surprising that a very common condition and a very common condition would coexist. And so I think one of the big challenges in cancer and stroke is when is the cancer causing the stroke versus when is the cancer present that has not a direct association with the stroke. And I think we’re still grappling with that in the field, but there seems to be what I would say a dominant phenotype situation where some patients, especially with adenocarcinomas, advanced cancers, metastatic cancers, develop a very aggressive coagulopathy, cancer-associated coagulopathy, that have very clear features, clinical features that most clinicians can detect...

Cancer obviously is one of the most common conditions. And so it’s not surprising that a very common condition and a very common condition would coexist. And so I think one of the big challenges in cancer and stroke is when is the cancer causing the stroke versus when is the cancer present that has not a direct association with the stroke. And I think we’re still grappling with that in the field, but there seems to be what I would say a dominant phenotype situation where some patients, especially with adenocarcinomas, advanced cancers, metastatic cancers, develop a very aggressive coagulopathy, cancer-associated coagulopathy, that have very clear features, clinical features that most clinicians can detect. And that is the three vascular territory pattern of diffusion abnormalities and the presence of a very elevated D-dimer, usually at least above three or higher. It’s that dominant group within a broader cancer and stroke population that I think we need to focus our energy on now and try to determine what the best treatment course for these patients are because their recurrence risk is so high. It can be as high as 30% at one month in some studies. So it’s a key area of stroke that badly needs a refined approach to management.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.